Supreme Court Temporarily Restores Mifepristone Mail Access, Blocks 5th Circuit Ruling

The U.S. Supreme Court on Monday temporarily restored broad access to the abortion pill mifepristone, blocking a lower-court ruling that had threatened to upend one of the main ways abortions are provided across the nation.

The order signed by Justice Samuel Alito temporarily allows women seeking abortions to obtain the pill at pharmacies or through the mail, without an in-person visit to a doctor, and it remains in effect for another week while both sides respond and the high court considers the issue more fully.

ABC News

AP described the order as restoring access “through telehealth, mail and pharmacies,” while ABC News said Alito issued an “administrative stay” that restores expanded access “for now.”

Multiple outlets tied the temporary pause to the Supreme Court’s emergency docket and to the New Orleans-based 5th U.S. Circuit Court of Appeals ruling that had reinstated a requirement that the drug can only be picked up in person.

CNN similarly said the stay “lasts through May 11,” and NBC News reported that Alito’s order would remain on hold until at least May 11.

The Guardian framed the move as pausing a fifth U.S. circuit court of appeals ruling that had imposed new limits on the drug, and it reported that Alito’s order would remain in effect until at least 5pm ET on 11 May.

In the background of the legal fight, the Supreme Court’s action was also described as giving time for the high court to consider next steps as it weighs separate emergency requests filed by drugmakers Danco and GenBioPro.

The Supreme Court’s temporary restoration came after a Friday ruling from the U.S. Court of Appeals for the 5th Circuit in New Orleans reinstated a requirement that mifepristone can only be picked up in person, a change that threatened to restrict access nationwide.

Reuters’ account in the Washington Post package described the Friday 5th Circuit decision as reinstating the in-person pickup requirement, and it said the Supreme Court’s decision came after two drugmakers filed emergency appeals challenging that Friday ruling.

ABC News

ABC News said the 5th Circuit order barred the commonly used abortion drug from being dispensed by telehealth providers or distributed by mail as litigation continues, and it said the order was effective immediately.

The Guardian said the Friday restrictions came from a conservative three-judge panel at an appellate courthouse in New Orleans that is widely considered one of the most conservative in the US, and it described the panel’s ruling as calling for preventing abortion providers from prescribing mifepristone through the mail.

NBC News described the Friday nationwide jeopardy as tied to the appeals court granting Louisiana’s request to void Biden administration rules that allowed the drug to be administered without an in-person meeting, meaning it can in theory be mailed anywhere in the country, even in states with strict abortion bans.

AP said the Supreme Court order temporarily allows pharmacies or mail access “without an in-person visit to a doctor,” and it characterized the stay as blocking the lower-court ruling that had threatened to upend access.

CNN similarly said the order puts on hold the 5th Circuit decision that reinstated a nationwide requirement that the medication be obtained in person, undermining access to the method of abortion that has grown more widespread since the court overturned Roe v. Wade.

Across the accounts, the legal fight was tied to Louisiana’s lawsuit against the Food and Drug Administration, with AP saying Louisiana sued to roll back the FDA’s rules on how mifepristone can be prescribed and NBC News saying Louisiana Attorney General Liz Murrill and the Alliance Defending Freedom alleged data did not support lifting the in-person dispensing requirement.

The emergency appeals and the Supreme Court’s stay were framed by both sides as a fight over patient access, regulatory process, and safety.

Danco Laboratories’ lawyers argued that the 5th Circuit decision created “the resulting chaos for patients, providers, pharmacies, and the drug-regulatory system is a quintessential irreparable harm that underscores the need for emergency relief from this Court,” according to ABC News, and CNN reported that Danco told the Supreme Court in its appeal that the 5th Circuit order “injects immediate confusion and upheaval into highly time-sensitive medical decisions.”

GenBioPro’s appeal, as described by CNN, said the lower court’s decision risked “abruptly cutting off access for patients nationwide.”

Anti-abortion groups, meanwhile, vowed to continue the legal battle, and AP quoted Carol Tobias, president of National Right to Life, saying the Monday ruling “is a temporary procedural step that leaves unresolved the very real concerns about the safety of these drugs and the decision under the Biden administration’s FDA to recklessly remove longstanding safeguards.”

Louisiana Attorney General Liz Murrill criticized drug companies for their role, and CNN and NBC News both quoted her statement that “Big abortion pharma claims they need an emergency stay because they will lose massive amounts of money if they can’t kill more babies quickly and efficiently by mail without medical oversight,” while NBC News also quoted her saying “The administrative stay is temporary, and I am confident life and the law will win in the end.”

On the abortion-rights side, Planned Parenthood Action Fund president Alexis McGill Johnson welcomed the decision and said, “While mifepristone access returns to where it was on Friday morning, the whiplash and chaos that patients and providers are navigating have already had real consequences for real peoples’ lives and futures,” a quote repeated by NBC News and Politico.

A C L U Reproductive Freedom Project attorney Julia Kaye said, “While this is a positive short-term development, no one can rest easy when our ability to get this safe, effective medication for abortion and miscarriage care still hangs in the balance,” according to the Guardian.

Dr. Angel Foster, founder of The Massachusetts Abortion Access Project, told AP that “Regardless of what happens with this regulatory issue, we and other groups will continue to provide high-quality abortion care to patients in all 50 states,” and she said, “We have a little bit more time to navigate this new landscape with the stay,” as AP quoted Julie Burkhart of Wellspring Health Access.

The temporary restoration immediately affected how abortion providers and advocacy groups planned for the next days, with some organizations preparing to switch regimens and others pausing services.

AP reported that Dr. Angel Foster said her organization was prepared to send misoprostol only on Monday afternoon but was able to switch back to the two-drug combination, and she said, “Regardless of what happens with this regulatory issue, we and other groups will continue to provide high-quality abortion care to patients in all 50 states.”

ACI Prensa

AP also described how Foster spent the weekend guiding different groups of patients, including those who were sent mifepristone but had not received it yet and those who reached out with initial requests, and it said for now they were asking patients to approve being sent pills with or without mifepristone.

CNN reported that the order was “far from a final decision” and maintained the status quo for a few days while the court reviews emergency appeals filed Saturday by the drug’s manufacturer and the maker of a generic version.

Politico reported that some telehealth abortion providers paused their services entirely after Friday’s 5th Circuit ruling, while others pivoted to only sending the second pill in the two-pill regimen—misoprostol—because it can end pregnancies on its own.

Politico also said misoprostol is more difficult to ban or restrict because it is used for an array of other purposes, including treating ulcers and stopping hemorrhages.

NBC News described the underlying medical framework as mifepristone being taken with a second drug, misoprostol, and it said the combination completes medical abortion 97.4% of the time, according to the FDA label on mifepristone as described by AP.

AP also said misoprostol can be used alone for terminating pregnancies, with some studies putting its effectiveness at around 80% or higher, and it said misoprostol has never been formally approved by the FDA for abortion.

In the legal guidance space, AP quoted Elizabeth Ling, associate director of legal services at If/When/How, saying, “The outcome is not going to make it a crime for people to access care,” and it said none of the state laws currently include any punishment for women who obtain abortions.

Across the accounts, the stay’s timing was central to operational planning, with ABC News saying the order from Alito is set to expire May 11 and CNN and NBC News both describing the stay as lasting through May 11.

The stay is explicitly temporary, and the sources describe a fast-moving schedule for responses and further Supreme Court consideration.

ABC News said the order from Alito is set to expire May 11, suggesting the full court will act by that time on whether to grant an extended stay of the lower court ruling as litigation over safety guidelines continues.

ADF Media

CNN said Alito’s order staying the 5th Circuit ruling lasts through May 11, and it said Alito requested a response in the cases by Thursday.

NBC News reported that Alito ordered Louisiana to file its response to the companies’ request by the end of the day Thursday, and it said the temporary pause gives the high court time to consider next steps as it weighs separate emergency requests filed by drugmakers Danco and GenBioPro.

Politico reported that Alito’s order is in effect through May 11, giving all nine justices time to consider requests from the drug’s manufacturers to keep the appeals court’s ruling on ice while the Supreme Court considers whether to take up the issue.

The Guardian said Alito said his order would remain in effect until at least 5pm ET on 11 May and that he had given Louisiana until 5pm ET on Thursday to respond.

AP described the order as remaining in effect for another week while both sides respond and the high court considers the issue more fully.

Beyond the immediate procedural deadlines, the sources also describe how the case fits into a broader legal timeline, including the Supreme Court’s 2024 unanimous rejection of a similar challenge to mifepristone access and the 2022 Supreme Court ruling that overturned Roe v. Wade.

AP said the 2024 Supreme Court ruling overturned Roe v. Wade in 2022 and that the latest order will remain in effect while the high court considers the issue more fully, and it also said the case questioned the safety of the drug, which was approved 25 years ago and has repeatedly been deemed safe and effective by FDA scientists.

NBC News said the new case focuses more narrowly on the Biden administration’s decision the previous year to make permanent Covid-era rules that made it easier to obtain the drug during the pandemic, and it said the FDA requested the case be paused until the agency finished conducting its own safety review of mifepristone.

In parallel, Politico reported that anti-abortion activists were pressuring the Justice Department to cut off all abortion medications by reviving the Comstock Act, a long dormant anti-obscenity law from the 1800s that prohibits mail delivery of any abortifacient, and it quoted Kristan Hawkins saying Alito allowed “pill pushers [to] receive every benefit of the doubt.”